What are the key steps to effective delivery of PrEP care?

Roger Pebody
Published: 20 January 2017

Providing pre-exposure prophylaxis (PrEP) to people who need it entails at least nine key steps, which can be conceived of as a PrEP continuum of care, according to an article published online ahead of print by Amy Nunn and colleagues in AIDS. This continuum can help define benchmarks by which progress in implementing PrEP in different programmes can be compared.

This is one of several recent articles which have attempted to define a continuum of care for PrEP or other HIV prevention interventions, adapting the concept of the ‘treatment cascade’ or the ‘continuum of care’ that is used in relation to HIV treatment.

The HIV treatment continuum of care has helped identify the sequence of events which are needed for treatment to have its desired effect – diagnosis, linkage to care, retention in care, receiving HIV treatment and adherence to it. Moreover, UNAIDS’ 90-90-90 targets reflect three key points within this continuum of care. The targets have been used to focus attention on improving uptake of key interventions that are essential to the health of people living with HIV.

If there were consensus about the key steps in relation to PrEP, this might also help focus attention and improve implementation.

Nunn and colleagues say that their model is based on experience implementing PrEP in Providence, Rhode Island and other sites in the United States. Each of the steps that are included presents opportunities for patients to continue using PrEP or to disengage from care – they are therefore important points of intervention.

The steps move from awareness to accessing healthcare, and then to adherence and retention.

1. Identify individuals at highest risk of HIV.

2. Increase those individuals’ awareness of their risk of HIV.

3. Enhance those individuals’ awareness of PrEP.

4. Facilitate access to PrEP, in other words potential users schedule an appointment with a suitable medical provider and have appropriate health insurance.

5. Link to PrEP care, in other words potential users attend their appointment.

6. Prescribe PrEP to those who meet clinical criteria.

7. Initiate PrEP: users start to take the medications.

8. Adhere to PrEP: users consistently take the medications.

9. Retain individuals in PrEP care.

The authors note that defining who is retained in care is challenging. PrEP is understood to be appropriate for ‘seasons of risk’, so many people will withdraw from PrEP care in a way that is entirely appropriate. Retention should be measured with reference in four distinct groups of people – individuals who need PrEP who are retained in care, individuals who need PrEP who are not retained in care, individuals who no longer need PrEP, and individuals lost to follow-up.

In this publication, the authors don’t propose data sources that could be used to compare different programmes or localities. Just as many countries have difficulty estimating the proportion of people living with HIV who remain undiagnosed (for measuring progress to 90-90-90), having reliable data to estimate the size of the population at highest risk of HIV and the proportion of that group aware of PrEP will be challenging in many settings. Nonetheless, setting targets may spur data collection.

The model builds upon and adds additional stages to a continuum that was published by Colleen Kelley and colleagues in 2015. That was a four-stage continuum (aware of PrEP and willing to use it; have access to healthcare; eligible for PrEP; adhere to PrEP). The new model suggests that the continuum of care is more complex and suggests a series of opportunities for intervention.

However a simpler continuum might be more useful for setting targets and as an advocacy tool. For example, by including access to healthcare as one of the four stages in the continuum, Kelley focuses attention on the way in which exclusion from health insurance restricts the uptake of PrEP in the United States.

And while these models may appear comprehensive, it is notable that they do not fully encompass one of the three key stages of the HIV prevention cascade that were described by James Hargreaves and colleagues in The Lancet HIV last year.  According to Hargreaves, for any HIV prevention product, procedure or behaviour we need to consider supply, demand and adherence. By including awareness, adherence and retention, Nunn’s continuum reflects the latter two.

But it focuses attention on the individual who may take PrEP and can only indirectly measure problems with the supply of PrEP, in other words problems with the health system. The coverage of PrEP could be low because only a few clinical services offer PrEP, they are inappropriate for the people who need it, or physicians have doubts about the merits of PrEP.

The interventions needed to increase the coverage of PrEP might not only be demand-creation or adherence-support, but the creation of more accessible health services, services to help people obtain health insurance, physician education, or the removal of legal barriers to providing PrEP to people under the age of 18.


Nunn A et al. Defining the HIV Pre-Exposure Prophylaxis Care Continuum. AIDS, online ahead of print, 2017.

Kelley C et al. Applying a PrEP Continuum of Care for Men Who Have Sex With Men in Atlanta, Georgia. Clinical Infectious Diseases 61:1590-1597, 2015.

Hargreaves J et al. The HIV prevention cascade: integrating theories of epidemiological, behavioural, and social science into programme design and monitoring. The Lancet HIV 3: e318-22, 2016.

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.